Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHENASDAQ:AYTUNASDAQ:CALCNASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$3.93+0.3%$4.16$1.00▼$5.87$34.86M0.8145,111 shs66,743 shsAYTUAytu BioPharma$2.10-0.9%$1.69$0.95▼$2.96$18.86M0.05372,609 shs57,998 shsCALCCalciMedica$1.43$1.73$1.43▼$5.97$19.98M1.2641,932 shs59,066 shsLEXXLexaria Bioscience$0.85-1.2%$1.07$0.82▼$4.38$14.91M0.84148,424 shs62,712 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics0.00%-7.09%-11.88%+15.90%+117.13%AYTUAytu BioPharma0.00%+5.00%+17.98%+75.00%-28.08%CALCCalciMedica0.00%-12.80%-14.08%-25.13%-63.89%LEXXLexaria Bioscience0.00%-11.56%-15.94%-50.35%-69.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics2.6638 of 5 stars3.35.00.00.02.21.70.0AYTUAytu BioPharma0.7298 of 5 stars0.02.00.03.42.10.00.6CALCCalciMedica3.1948 of 5 stars3.54.00.00.02.63.30.0LEXXLexaria Bioscience3.2172 of 5 stars3.54.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00205.34% UpsideAYTUAytu BioPharma 0.00N/AN/AN/ACALCCalciMedica 3.00Buy$18.001,158.74% UpsideLEXXLexaria Bioscience 3.00Buy$7.00724.50% UpsideCurrent Analyst Ratings BreakdownLatest AYTU, LEXX, ATHE, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AAYTUAytu BioPharma$81M0.23N/AN/A$4.64 per share0.45CALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/ALEXXLexaria Bioscience$460K32.41N/AN/A$0.48 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%N/ACALCCalciMedica-$13.70M-$1.56N/AN/AN/AN/A-171.81%-100.43%8/11/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,784.03%-111.84%-100.48%7/11/2025 (Estimated)Latest AYTU, LEXX, ATHE, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/11/2025N/ALEXXLexaria Bioscience-$0.15N/AN/AN/A$0.17 millionN/A5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.84N/AAYTUAytu BioPharma0.271.030.87CALCCalciMedica0.795.665.66LEXXLexaria BioscienceN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%AYTUAytu BioPharma33.49%CALCCalciMedicaN/ALEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%AYTUAytu BioPharma3.60%CALCCalciMedica41.55%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableCALCCalciMedica3013.97 million8.17 millionNo DataLEXXLexaria Bioscience717.56 million12.92 millionNot OptionableAYTU, LEXX, ATHE, and CALC HeadlinesRecent News About These CompaniesLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | accessnewswire.comALexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | thenewswire.comTLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | accessnewswire.comALexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | thenewswire.comTLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Attending BIO International ConventionJune 5, 2025 | accessnewswire.comALexaria Attending BIO International ConventionJune 5, 2025 | thenewswire.comTLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | thenewswire.comTLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | accessnewswire.comALexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | accessnewswire.comALexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | thenewswire.comTLexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | thenewswire.comTLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | accessnewswire.comALexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyApril 23, 2025 | accessnewswire.comAWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | thenewswire.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYTU, LEXX, ATHE, and CALC Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$3.93 +0.01 (+0.26%) Closing price 06/27/2025 03:57 PM EasternExtended Trading$4.00 +0.06 (+1.65%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Aytu BioPharma NASDAQ:AYTU$2.10 -0.02 (-0.94%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.08 -0.02 (-1.19%) As of 06/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.CalciMedica NASDAQ:CALC$1.43 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.52 +0.10 (+6.64%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Lexaria Bioscience NASDAQ:LEXX$0.85 -0.01 (-1.23%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.53%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
